Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02349295 · ClinicalTrials.gov registry record · Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 363
- Enrollment target
NCT02349295: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT02349295 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 363 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02349295, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 363 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.
Primary Outcome
ACR20 response is defined as a greater than or equal to (≥) 20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain visual analog scale (VAS), Participant's Global Assessment of Disease Activity VAS (PatGA), Physician's Global Assessment of the Disease Activity VAS (PGA), Participant's Assessment of Physical Function using the Health Assessment Questionnaire Disability Index (HA
Interventions
- DRUG Placebo
- DRUG Ixekizumab 80 mg Q4W
- DRUG Ixekizumab 80 mg Q2W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2014-12-31 |
| Est. Completion | 2019-06-26 |
| Phase | Phase 3 |
What the finished NCT02349295 record still lists
NCT02349295 is an interventional study that assigns participants to a tested intervention. The registered 363 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02349295 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02349295 about?
NCT02349295 is a clinical study titled "A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis". The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.
What is the current status of trial NCT02349295?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 363 participants. The study started on 2014-12-31. Estimated completion is 2019-06-26.
What interventions are being tested in trial NCT02349295?
The interventions under investigation include: Placebo (DRUG), Ixekizumab 80 mg Q4W (DRUG), Ixekizumab 80 mg Q2W (DRUG).
Who is sponsoring clinical trial NCT02349295?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02349295's enrollment target sits among peer trials
363 1005th of 2000 higher than 994 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- NCT04510597 · 364 participants · Phase 3
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- NCT05098132 · 364 participants · Phase 1
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- NCT05330221 · 364 participants · NA
Project 2: ACHIEVE- HF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI